Background: Biologic treatments for cancer continue to place a significant economic burden on healthcare stakeholders. Biosimilar therapies may help reduce this burden through cost savings, thereby increasing patient access.
Objectives: The purpose of this study was to collate all published data to assess the weight of available evidence (quantity and quality) for proposed monoclonal antibody biosimilars and intended copies, for the treatment of cancer.
Methods: MEDLINE, Embase, and ISI Web of Science databases were searched to September 2015. Conference proceedings (17) were searched (2012 to July 2015). Searches of the United States National Library of Medicine ClinicalTrials.gov registry were also conducted. Risk of bias assessments were undertaken to assess data strength and validity.
Results: Proposed biosimilars were identified in 23 studies (36 publications) in oncology and ten studies in 14 publications in oncology and chronic inflammatory diseases for bevacizumab, rituximab, and trastuzumab originators. Based on our review of the included published studies, and as inferred from the conclusions of study authors, the identified proposed biosimilars exhibit close similarity to their originators. Published data were also retrieved on intended copies of rituximab. It remains unclear what role these agents may have, as publications on rigorous clinical studies are lacking for these molecules.
Conclusion: While biosimilar products have the potential to improve patient access to important biologic therapies, robust evidence of outcomes for monoclonal antibody biosimilars in treating cancer patients, including data from comparative efficacy and safety trials, is not yet available in the published literature. Significant data gaps exist, particularly for intended copies, which reinforces the need to maintain a clear differentiation between these molecules and true biosimilars. As more biosimilars become available for use, it will be important for stakeholders to understand fully the robustness of overall evidence used to demonstrate biosimilarity and gain regulatory approval.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5258783 | PMC |
| http://dx.doi.org/10.1007/s40259-016-0207-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Turning the Page on Hardcopy Risk Management Plan Educational Materials: Digitalization Made Possible.
Ther Innov Regul Sci
November 2024
Novartis Healthcare Private Limited, Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra (East), 400 051, Mumbai, India.
'Risk Management Plan Educational Materials' (RMP EMs) are additional risk minimization measures (aRMMs) intended to prevent or reduce the occurrence of adverse reactions associated with the exposure to a medicine, or to reduce their severity or impact on the patient. While the healthcare sector is embracing various digital tools and platforms for educational and/or awareness building purposes, paper-based materials have remained the mainstay approach for implementation of aRMMs by pharmaceutical companies. Novartis in Singapore conducted a pilot on the feasibility of distributing electronic copies of RMP EMs (e-RMP).
View Article and Find Full Text PDFDeterminants of antimicrobial resistance in biosolids: A systematic review, database, and meta-analysis.
Sci Total Environ
December 2024
The Biodesign Institute Center for Environmental Health Engineering, Arizona State University, 1001 S. McAllister Ave, Tempe, AZ 85281, USA; School of Sustainable Engineering and the Built Environment, Arizona State University, Tempe, AZ 85281, USA. Electronic address:
Biosolids can provide a nutrient rich soil amendment, particularly for poor soils and semi-arid or drought-prone areas. However, there are concerns that sludge and biosolids could be a source of propagation and exposure to AMR determinants such as antibiotic resistant bacteria (ARB), and antibiotic resistance genes (ARGs). To inform risk assessment efforts, a systematic literature review was performed to build a comprehensive spreadsheet database of ARB and ARG concentrations in biosolids (and some sludges specified as intended for land application), along with 69 other quantitative and qualitative meta-data fields from 68 published studies describing sampling information and processing methods that can be used for modeling purposes.
View Article and Find Full Text PDFDetection of hepatitis B virus genotypes in a group of hepatitis B virus-infected patients in central and northern Sri Lanka.
Access Microbiol
October 2024
National Hospital, Kandy 20000, Sri Lanka.
Hepatitis B infection causes a spectrum of clinical diseases varying from asymptomatic infection to severe or fulminant acute hepatitis, chronic liver disease, cirrhosis and hepatocellular carcinoma. Hepatitis B virus (HBV) genotypes appear to influence transmission dynamics, clinical outcomes and responses to antiviral therapy. However, hepatitis B genotyping has been poorly investigated in Sri Lanka.
View Article and Find Full Text PDFOutcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.
Muscle Nerve
December 2024
Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Article Synopsis
- This study looked at how early treatment helps babies with spinal muscular atrophy (SMA), a condition that affects muscles.
- Researchers checked the health of 66 babies treated within the first 6 weeks of life and found good results, like all babies being able to sit up on their own.
- However, some babies with a certain genetic marker (two SMN2 copies) had a harder time walking compared to those with more copies, showing that more studies are needed to improve their care.
Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients.
Best Pract Res Clin Endocrinol Metab
September 2024
Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, DMU Carte, Unité Hypertension Artérielle, Centre de références en maladies rares de la surrénale, Paris Centre de Recherche Cardiovasculaire, INSERM, Paris, France. Electronic address:
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a strong genetic predisposition, involving over 20 genes and with germline pathogenic variants identified in 40 % of cases. The succinate dehydrogenase (SDHx) genes are the most commonly implicated in hereditary PPGLs, accounting for 20 % of cases, and present unique diagnostic and treatment challenges due to their potential for multiple, recurrent, and aggressive manifestations, often necessitating lifelong follow-up. Over the past two decades, advances in biochemical and imaging assessments, management, and follow-up protocols have significantly improved care for both adult and paediatric patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!